Clinical Trial Search

Primary: Pain Intensity Difference (PID) at 15 Minutes Post-treatment (PID15) — 0.88; 0.76 Units on scale — p=0.0004

Primary: Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30) — 640.3; 399.6 Units on a scale

Primary: Pain Intensity Difference (PID15) At 15 Minutes — 0.82; 0.59 Units on a scale — p=<0.0001

Primary: Percentage of Participants With Adverse Events. — 88.5 percentage of participants

Primary: Summary of Pain Intensity Differences (SPID) — 47.9; 38.1 Score on a scale — p=0.004

Primary: Percentage of Cancer Participants With Breakthrough Cancer Pain From the Total Number of Cancer Participants Seen in Consultation — 14.3 percentage of participants

Primary: Change From Baseline in the Numerical Rating Pain Scale (NRS) — 1.87; 1.81 units on a scale

Primary: Number of Subjects With Success Rate at 15 Minutes Post-epidural Bolus Injection — 31; 38 Participants — p=0.38

Primary: Retention Rate — 100; 100 percentage of participants

Primary: Time to Analgesia — 10; 35 minutes

Primary: Time-weighted SPID30 — 59.9; 42.6 units on a scale — p=<0.001

Primary: Percentage of Patients That Experienced 1 or More Adverse Events — 59.0; 80.7 Percentage of patients

Primary: Dose of Instanyl — 75; 30; 50; 69 participants

Primary: Dyspnea Numeric Rating Scale — -2.4; -1.1 score on a scale

Primary: Pain on the Average, Mean Change From Baseline Days 21-84 (Last Observation Carried Forward [LOCF]) — -1.01; -1.82; -1.92 Units on a scale — p=0.0350

Primary: Average Pain Over the Last 24 Hours Scores at Week 12 of the Double-blind Phase. — 7.24; 7.17; 2.57; 2.56 Units on a scale — p=.0104

Primary: Induction Phase: Pain Intensity Difference at 10 Minutes (PID10) After Treatment — 2.5; 1.4 units on a scale — p=0.002

Primary: The Number of Subjects With Ineffective Treatment During the Double-blind Evaluation Phase. — 89; 66; 155; 81 participants — p=.0217

Primary: Modified Dyspnea Borg Scale (Dyspnea Intensity) — -1.4; -0.5 score on a scale

Primary: "Average Pain Over the Last 24 Hours" Score of the Study Knee at Week 12 of the Double Blind Phase. — 7.16; 7.06; 2.63; 2.74 units on a scale — p=0.0853

Primary: Percentage of Participants With Dosing Frequency of Analgesics for Treating Breakthrough Pain — 50.9 Percentage of Participants

Primary: Change in Box Scale-11 (BS-11) Pain Score — 6.2; 4.0 units on a scale

Primary: Pain Interference Based on the Brief Pain Inventory — 5.01; 4.67 units on a scale

Primary: Visual Analog Scale (VAS) for Pain — 46.88; 48.60; 46.76 units on a scale

Primary: The Time (Days) From First Administration of Double-blind Treatment to the Development of Inadequate Analgesia at the Primary Osteoarthritis Pain Site. — 12.3; 17.2 days…

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 33; 47 Participants

Primary: Dyspnea Numeric Rating Scale — -2.0; -1.7; -2.3; -2.5 score on a scale

Primary: Median Time to Significant Analgesia (at Least 2 Units Decrease in Pain Level) — 15.0; 20.0; 15.0; 15.0 minutes

Primary: Proportion of Non-Responder (NR) Participants — 14; 18; 14; 11 participants

Primary: Pain Intensity — 5.60; 6.44; 5.11; 5.98 units on a scale